Pfizer (PFE) Long-Term Investments (2009 - 2026)

Pfizer (PFE) has reported Long-Term Investments for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Investments fell 26.46% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 26.46% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 27.24% from the prior year.
• Long-Term Investments was $1.6 billion for Q2 2026 at Pfizer, down from $1.6 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $20.7 billion in Q2 2022 and troughed at $1.6 billion in Q2 2026.
• A 5-year average of $9.2 billion and a median of $11.0 billion in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments increased 2.52% in 2022 and plunged 85.5% in 2024, its largest moves.
• Over 5 years, Long-Term Investments stood at $15.1 billion in 2022, then rose by 1.98% to $15.4 billion in 2023, then sank by 85.5% to $2.2 billion in 2024, then decreased by 27.24% to $1.6 billion in 2025, then dropped by 3.82% to $1.6 billion in 2026.
• The last three Long-Term Investments figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.